View by Specialty

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

Steatohepatitis/Metabolic Liver Disease News

SPONSORED CONTENT
Save
SPONSORED CONTENT
November 30, 2023
2 min read
Save

Pegozafermin improves stage 4 fibrosis, noninvasive markers in MASH patients

Pegozafermin improves stage 4 fibrosis, noninvasive markers in MASH patients

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

SPONSORED CONTENT
November 28, 2023
2 min read
Save

Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH

Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

SPONSORED CONTENT
November 27, 2023
2 min read
Save

ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48

ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48

Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.

SPONSORED CONTENT
November 22, 2023
2 min read
Save

Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin

Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.

SPONSORED CONTENT
November 21, 2023
3 min read
Save

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

SPONSORED CONTENT
November 21, 2023
2 min read
Save

High ultra-processed food intake linked to increased MASLD risk in adolescents, adults

High ultra-processed food intake linked to increased MASLD risk in adolescents, adults

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.

SPONSORED CONTENT
November 21, 2023
2 min read
Save

Low-dose aspirin ‘potential therapeutic option’ for MASLD, markedly reduces steatosis

Low-dose aspirin ‘potential therapeutic option’ for MASLD, markedly reduces steatosis

BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.

SPONSORED CONTENT
November 15, 2023
4 min watch
Save

VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH

VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

SPONSORED CONTENT
November 14, 2023
2 min read
Save

‘Significant differences’ reported by race, ethnicity in transplant rates for MASH-HCC

‘Significant differences’ reported by race, ethnicity in transplant rates for MASH-HCC

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

SPONSORED CONTENT
November 13, 2023
2 min read
Save

MASH resolution without worsening fibrosis boosts 15-year survival after bariatric surgery

MASH resolution without worsening fibrosis boosts 15-year survival after bariatric surgery

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails